Investors Buy Large Volume of Astrazeneca Call Options (NYSE:AZN)

Key Points

• AstraZeneca call-option activity surged: Traders bought 49,737 call options, about 1,415% above the typical volume, signaling heightened bullish speculation but not necessarily a fundamental shift in valuation.
• Pipeline and analyst sentiment remain supportive: AstraZeneca announced an AI drug-discovery partnership with Insitro worth up to $1.5 billion, while RBC maintained an “outperform” rating and a 14,500-pence target. Overall, analysts rate the stock “Moderate Buy,” with a $206.67 average price target.
• Shares rose 3.5% to $167.66: Institutional investors increased their holdings, including Assenagon Asset Management, which nearly doubled its position in the third quarter. AstraZeneca’s latest quarterly EPS beat expectations, although revenue fell slightly short of estimates.

Astrazeneca Plc (NYSE:AZN - Get Free Report) saw some unusual options trading on Thursday. Traders purchased 49,737 call options on the stock. This is an increase of approximately 1,415% compared to the typical volume of 3,284 call options.

Key Headlines Impacting Astrazeneca

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: AI drug-discovery partnership: AstraZeneca agreed to work with Insitro on therapies for metabolic dysfunction-associated steatohepatitis (MASH) and cardiometabolic disease. The deal includes approximately $40 million in upfront payments and could be worth up to $1.5 billion through development, regulatory and commercial milestones. The agreement gives AstraZeneca access to Insitro’s machine-learning capabilities and potential new candidates, supporting the company’s longer-term pipeline strategy. AstraZeneca Strikes Up to $1.5 Billion AI Drug Discovery Deal With Insitro
• Positive Sentiment: Supportive RBC outlook: RBC Capital Markets reiterated its “outperform” rating and 14,500-pence price target. The bank expects third-quarter revenue of $16.3 billion and core EPS of $2.61, both modestly ahead of consensus, while investors await results on October 30 and updates on the AVANZAR lung-cancer trial. RBC keeps AstraZeneca at outperform ahead of AVANZAR lung cancer trial
• Neutral Sentiment: Options activity surged: Investors bought nearly 49,737 call options, roughly 15 times typical daily call volume. This indicates heightened bullish speculation, but options activity alone does not confirm sustained buying or a fundamental change in valuation.
• Neutral Sentiment: Mixed rating signal: Zacks Research upgraded AstraZeneca from “strong sell” to “hold,” reducing a negative ratings overhang but stopping short of a bullish recommendation. Zacks rating update

Analyst Ratings Changes

A number of research firms have weighed in on AZN. Citigroup restated a "buy" rating on shares of Astrazeneca in a research report on Tuesday, October 6th. Bank of America reiterated a "buy" rating on shares of Astrazeneca in a research report on Wednesday, July 1st. Wall Street Zen downgraded Astrazeneca from a "buy" rating to a "hold" rating in a research report on Sunday. Deutsche Bank Aktiengesellschaft raised shares of Astrazeneca from a "sell" rating to a "hold" rating in a research note on Tuesday, September 15th. Finally, Zacks Research upgraded shares of Astrazeneca from a "strong sell" rating to a "hold" rating in a research report on Tuesday. Fifteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $206.67.

Institutional Investors Weigh In On Astrazeneca

Large investors have recently added to or reduced their stakes in the stock. Assenagon Asset Management S.A. grew its position in shares of Astrazeneca by 96.8% during the third quarter. Assenagon Asset Management S.A. now owns 2,660,409 shares of the company's stock worth $429,826,000 after acquiring an additional 1,308,232 shares during the last quarter. Elevated Private Wealth LLC lifted its position in Astrazeneca by 2.4% in the 3rd quarter. Elevated Private Wealth LLC now owns 6,376 shares of the company's stock valued at $1,030,000 after purchasing an additional 150 shares during the last quarter. RDA Financial Network boosted its stake in Astrazeneca by 34.2% during the 3rd quarter. RDA Financial Network now owns 1,456 shares of the company's stock valued at $235,000 after purchasing an additional 371 shares during the period. PFG Private Wealth Management LLC grew its position in Astrazeneca by 26.6% in the 3rd quarter. PFG Private Wealth Management LLC now owns 2,241 shares of the company's stock worth $362,000 after purchasing an additional 471 shares during the last quarter. Finally, Ninety One North America Inc. bought a new position in Astrazeneca in the 3rd quarter worth about $10,468,000. Institutional investors own 20.35% of the company's stock.

Astrazeneca Trading Up 3.5%

AZN stock traded up $5.63 during trading on Thursday, reaching $167.66. The company had a trading volume of 2,748,452 shares, compared to its average volume of 2,802,279. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.89 and a quick ratio of 0.67. Astrazeneca has a 52 week low of $153.41 and a 52 week high of $212.71. The business has a 50 day moving average of $161.96 and a 200 day moving average of $176.37. The company has a market cap of $260.03 billion, a P/E ratio of 25.06, a PEG ratio of 1.32 and a beta of 0.27.

Astrazeneca (NYSE:AZN - Get Free Report) last announced its quarterly earnings data on Monday, July 27th. The company reported $2.63 EPS for the quarter, beating the consensus estimate of $2.50 by $0.13. The business had revenue of $15.38 billion during the quarter, compared to analyst estimates of $15.44 billion. Astrazeneca had a return on equity of 31.45% and a net margin of 17.02%. The company's revenue for the quarter was up 6.4% on a year-over-year basis. During the same quarter last year, the firm posted $2.17 earnings per share. As a group, sell-side analysts forecast that Astrazeneca will post 9.38 earnings per share for the current fiscal year.

Astrazeneca Company Profile

AstraZeneca PLC is a global biopharmaceutical company headquartered in Cambridge, United Kingdom. Its research, development and commercial operations focus on prescription medicines for serious and chronic diseases, with an emphasis on discovering and delivering innovative therapies rather than operating as a diversified healthcare conglomerate.

The company's principal therapeutic areas include oncology; cardiovascular, renal and metabolic diseases; respiratory and immunological conditions; and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.